Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claus Garbe

Showing results (411-420 of 501) with videos related to

Pageof 51
Sort By:
The Lancet. Oncology|February 2, 2015
Expanded access programmes: patient interests versus clinical trial integrityPaul Lorigan, Paolo A Ascierto, Reinhard Dummer, et al.
The Lancet. Oncology|March 26, 2018
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trialReinhard Dummer, Paolo A Ascierto, Helen J Gogas, et al.
European Journal of Cancer (Oxford, England : 1990)|May 27, 2020
The EORTC-DeCOG nomogram adequately predicts outcomes of patients with sentinel node-positive melanoma without the need for completion lymph node dissectionDaniëlle Verver, A Rekkas, Claus Garbe, et al.
European Journal of Cancer (Oxford, England : 1990)|February 4, 2025
Diagnosis and treatment of dermatofibrosarcoma protuberans. European interdisciplinary guideline - update 2024Philippe Saiag, Celeste Lebbe, Lieve Brochez, et al.
European Journal of Cancer (Oxford, England : 1990)|December 1, 2023
Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapyNikolaus B Wagner, Max M Lenders, Kathrin Kühl, et al.
Journal of the American Academy of Dermatology|July 24, 2023
EGFR expression is associated with relapse in a melanoma cohort receiving adjuvant PD-1-based immunotherapyTeresa Amaral, Oltin Tiberiu Pop, Eftychia Chatziioannou, et al.
European Journal of Cancer (Oxford, England : 1990)|November 10, 2021
Corrigendum to 'Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)' [European Journal of Cancer 152 (2021) 116-128]Helen Gogas, Reinhard Dummer, Paolo A Ascierto, et al.
Journal for Immunotherapy of Cancer|December 22, 2021
Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapyJonas Bochem, Henning Zelba, Janine Spreuer, et al.
European Journal of Cancer (Oxford, England : 1990)|May 15, 2017
Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF<sup>V600</sup> mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysisChristian U Blank, James Larkin, Ana M Arance, et al.
Journal of Translational Medicine|July 24, 2019
Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy)Paolo A Ascierto, Sanjiv S Agarwala, Gerardo Botti, et al.
Pageof 51

Showing results (411-420 of 501) with videos related to

Sort By:
Pageof 51
The Lancet. Oncology|February 2, 2015
Expanded access programmes: patient interests versus clinical trial integrityPaul Lorigan, Paolo A Ascierto, Reinhard Dummer, et al.
The Lancet. Oncology|March 26, 2018
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trialReinhard Dummer, Paolo A Ascierto, Helen J Gogas, et al.
European Journal of Cancer (Oxford, England : 1990)|May 27, 2020
The EORTC-DeCOG nomogram adequately predicts outcomes of patients with sentinel node-positive melanoma without the need for completion lymph node dissectionDaniëlle Verver, A Rekkas, Claus Garbe, et al.
European Journal of Cancer (Oxford, England : 1990)|February 4, 2025
Diagnosis and treatment of dermatofibrosarcoma protuberans. European interdisciplinary guideline - update 2024Philippe Saiag, Celeste Lebbe, Lieve Brochez, et al.
European Journal of Cancer (Oxford, England : 1990)|December 1, 2023
Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapyNikolaus B Wagner, Max M Lenders, Kathrin Kühl, et al.
Journal of the American Academy of Dermatology|July 24, 2023
EGFR expression is associated with relapse in a melanoma cohort receiving adjuvant PD-1-based immunotherapyTeresa Amaral, Oltin Tiberiu Pop, Eftychia Chatziioannou, et al.
European Journal of Cancer (Oxford, England : 1990)|November 10, 2021
Corrigendum to 'Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)' [European Journal of Cancer 152 (2021) 116-128]Helen Gogas, Reinhard Dummer, Paolo A Ascierto, et al.
Journal for Immunotherapy of Cancer|December 22, 2021
Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapyJonas Bochem, Henning Zelba, Janine Spreuer, et al.
European Journal of Cancer (Oxford, England : 1990)|May 15, 2017
Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF<sup>V600</sup> mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysisChristian U Blank, James Larkin, Ana M Arance, et al.
Journal of Translational Medicine|July 24, 2019
Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy)Paolo A Ascierto, Sanjiv S Agarwala, Gerardo Botti, et al.
Pageof 51